Form 4: Alumis Inc. CEO Martin Babler Acquires 523,000 Stock Options

Alumis Inc.'s President, CEO, and Chairman, Martin Babler, reports the acquisition of 523,000 stock options with an exercise price of $5.06.

Summary

• Martin Babler, the President, CEO, and Chairman of Alumis Inc., filed a Form 4 with the SEC.
• The filing reports the acquisition of 523,000 stock options on February 18, 2025, with an exercise price of $5.06.
• The options vest over time, with 25% vesting on February 18, 2026, and the remainder vesting in equal monthly installments over the following 36 months, contingent upon continuous service.
• Following the transaction, Babler directly owns 523,000 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard executive compensation disclosure. The grant of options is generally viewed as a positive incentive, but the actual impact depends on the company's performance.

Positives

• The acquisition of stock options by the CEO could align his interests with those of the shareholders, incentivizing him to improve the company's performance.

Future Outlook

The vesting schedule of the options suggests a long-term commitment from the CEO to the company's success.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value creation.

Comparison to Industry Standards

• Executive compensation packages, including stock options, are common in the biotech industry to attract and retain talent.
• The vesting schedule and exercise price would need to be compared to similar companies like Gilead, Amgen, or Biogen to assess if they are in line with industry standards.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive incentive for the CEO.
• Employees may see it as a sign of confidence in the company's future.

Key Dates

Keywords

Form 4, Alumis Inc., Stock Options, Martin Babler, SEC Filing, Executive Compensation